Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Receivables - Other: 2022-2024

Historic Receivables - Other for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $700,000.

  • Stoke Therapeutics' Receivables - Other rose 129.96% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 129.96%. This contributed to the annual value of $700,000 for FY2024, which is 993.75% up from last year.
  • According to the latest figures from FY2024, Stoke Therapeutics' Receivables - Other is $700,000, which was up 993.75% from $64,000 recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Receivables - Other ranged from a high of $700,000 in FY2024 and a low of $64,000 during FY2023.
  • Over the past 3 years, Stoke Therapeutics' median Receivables - Other value was $588,000 (recorded in 2022), while the average stood at $450,667.
  • As far as peak fluctuations go, Stoke Therapeutics' Receivables - Other crashed by 89.12% in 2023, and later surged by 993.75% in 2024.
  • Yearly analysis of 3 years shows Stoke Therapeutics' Receivables - Other stood at $588,000 in 2022, then slumped by 89.12% to $64,000 in 2023, then surged by 993.75% to $700,000 in 2024.